Abstract
Emergence of the multidrug-resistant pathogens has rendered the current therapies ineffective thereby, resulting in the need for new drugs and drug targets. The accumulating protein sequence data has initiated a drift from classical drug discovery protocols to structure-based drug designing. In the present study, in silico subtractive genomics approach was implemented to find a set of potential drug targets present in an opportunist bacterial pathogen, Acinetobacter baumannii (A. baumannii). Out of the 43 targets identified, further studies for protein model building and lead-inhibitor identification were carried out on two cell-essential targets, MurA and MurB enzymes (of A. baumannii designated as MurAAb and MurBAb) involved in the peptidoglycan biosynthesis pathway of bacteria. The homology model built for each of them was further refined and validated using various available programs like PROCHECK, Errat, ProSA energy plots, etc. Compounds showing activity against MurA and MurB enzymes of other organisms were collected from the literature and were docked into the active site of MurAAb and MurBAb enzymes. Three inhibitors namely, T6361, carbidopa, and aesculin, showed maximum Glide score, hydrogen bonding interactions with the key amino acid residues of both the enzymes and acceptable ADME properties. Furthermore, molecular dynamics simulation studies on MurAAb–T6361 and MurBAb–T6361 complexes suggested that the ligand has a high binding affinity with both the enzymes and the hydrogen bonding with the key residues were stable in the dynamic condition also. Therefore, these ligands have been propsed as dual inhibitors and promising lead compounds for the drug design against MurAAb and MurBAb enzymes.
Similar content being viewed by others
References
Leepethacharat, K., & Oberdorfer, P. (2007). Journal Infectious Diseases Antimicrobial Agents, 24, 63–73.
Berezin, E. B. (1997). Expert Opinion Investigational Drugs, 6(2), 119–127.
Karageorgopoulos, D. E., & Falagas, M. E. (2008). Lancet, 8, 751–762.
Manchanda, V., et al. (2010). Jounal Global Infectious Disease, 2, 291–302.
Erridge, C., et al. (2007). Journal of Medical Microbiology, 56, 165–171.
Rahbar, M. R., et al. (2010). Journal of Theoretical Biology, 266, 275–290.
Perez, F. (2011). Virulence, 2(2), 86–90.
Lee, J. S., et al. (2007). Biochemical Pharmacology, 74, 86–97.
Vetrivel, U. (2011). The HUGO Journal, 5, 25–34.
Barh, D. (2011). Drug Development Research, 72, 162–177.
Schmid, M. B., et al. (2006). Biochemical Pharmacology, 71, 1048–1056.
Salemme, F. R. (1997). Structure, 5, 319–324.
Huynen, M. (1997). Trends in Genetics, 13, 389–390.
Huynen, M., et al. (1998). FEBS Letters, 426(1), 1–5.
Hillisch, A., et al. (2004). Drug Discovery Today, 9, 659–669.
Weiderstien, M., et al. (2007). Nucleic Acid Research, 36, 407–410.
Radha Kishan, K. V., et al. (2007). Current Protein & Peptide Science, 8, 376–380.
Kitchen, D. B., et al. (2004). Nature Reviews Drug Discovery, 3, 939–945.
Georrge, J. J., et al. (2012). Applied Biochemistry and Biotechnology, 167(5), 1377–1395.
Tondi, D., et al. (1999). Chemistry and Biology, 6, 319–331.
Fritz, T., et al. (2001). Chemistry and Biology, 8, 981–995.
Garg, A., et al. (2010). BMC Bioinformatics, 11(1), S53.
Garg, A., et al. (2010). BMC Bioinformatics, 11, 125.
The Uniprot Consortium. (2012). Nucleic Acids Research, 40, 71–75.
Zhang, R., & Lin, Y. (2009). Nucleic Acids Research, 37, D455–D458.
Li, W., & Godzik, A. (2006). Bioinformatics, 22(13), 1658–1659.
Altschul, S. F., et al. (1990). Journal of Molecular Biology, 215, 403–410.
Moriya, Y., et al. (2007). Nucleic Acids Research, 35, W182–W185.
Yu, N. Y., et al. (2010). Bioinformatics, 26(13), 1608–1615.
Sali, A., et al. (2000). Annual Review of Biophysics and Biomolecular Structure, 29, 291–325.
Laskowski, R. A., et al. (1993). Journal of Applied Crystallography, 26, 283–291.
Colovos, C., & Yeates, T. O. (1993). Protein Science, 2, 1511–1519.
Dundas, J., et al. (2006). Nucleic Acid Research, 34, W116–W118.
Barbosa, M. D., et al. (2002). Antimicrobial Agents and Chemotherapy, 46, 943–946.
Baum, E. Z., et al. (2001). Antimicrobial Agents and Chemotherapy, 45, 3182–3188.
Bachelier, A., et al. (2006). Bioorganic & Medicinal Chemistry Letters, 16, 5605–5609.
Mendgen, T. (2010). Bioorganic & Medicinal Chemistry Letters, 20, 5757–5762.
Fransisco, G. D., et al. (2004). Bioorganic & Medicinal Chemistry Letters, 14, 235–238.
Eschenburg, S., et al. (2005). Journal of Biological Chemistry, 280, 3757–3763.
Han, H., et al. (2010). Biochemistry, 49, 4276–4282.
Dunsmore, C. J., et al. (2008). Bioorganic & Medicinal Chemistry Letters, 18, 1730–1734.
Bronson, J. J., et al. (2003). Bioorganic & Medicinal Chemistry Letters, 13, 873–875.
Yang, Y., et al. (2006). Antimicrobial Agents and Chemotherapy, 50, 556–564.
Kutterer, K. M. K., et al. (2005). Bioorganic & Medicinal Chemistry Letters, 15, 2527–2531.
Anante, S., et al. (2006). Bioorganic & Medicinal Chemistry Letters, 16, 176–180.
Li, Z., et al. (2003). Bioorganic & Medicinal Chemistry Letters, 13, 2591–2594.
Sybyl 7.1, Tripos Inc, St. Louis, MO 63144, USA.
Maestro, version 9.0, Schrödinger, LLC, New York, NY, 2009.
Friesner, R. A., et al. (2004). Journal of Medicinal Chemistry, 47(7), 1739–1749.
QikProp, version 3.1. (2008). Schrödinger Inc., LLC, New York, USA.
Case, D. A., et al. (2010). AMBER 11. San Francisco: University of California.
Jorgensen, W. L., et al. (1983). Journal of Chemical Physics, 79, 926–935.
Darden, T., et al. (1993). Journal of Chemical Physics, 98, 10089–10092.
Verlet, L. (1967). Physical Review, 159, 98–103.
Ryckaert, J. P., et al. (1977). Journal of Computational Physics, 23, 327–341.
Srinivasan, J., et al. (1998). Journal of the American Chemical Society, 120, 9401–9409.
Gautam, A., et al. (2010). International Journal of Integrative Biology, 10(2), 66–75.
Gautam, A., et al. (2010). Critical Reviews in Biotechnology, 31(4), 295–336.
Bugg, T. D. H., et al. (2011). Trends Biotechnology, 29(4), 167–173.
Silver, L. L. (2003). Current Opinion in Microbiology, 6, 431–438.
Zoelby, A. E., et al. (2003). Molecular Microbiology, 47(1), 1–12.
Schneider, T., & Sahl, H. G. (2010). International Journal of Medical Microbiology, 300, 161–169.
Lopez, J. M., et al. (2006). Peptides, 27, 3115–3121.
Benson, T. E., et al. (1993). Biochemistry, 32, 2024–2030.
Kim, D. H., et al. (1996). Biochemistry, 35, 4923–4928.
Benson, T. E., et al. (1997). Biochemistry, 36, 806–811.
Skarzynski, T., et al. (1998). Biochemistry, 37(8), 2572–2577.
Jackson, S. G., et al. (2009). Biochemistry, 41, 11715–11723.
Thomas, A. M., et al. (2004). European Journal of Biochemistry, 271, 2682–2690.
Skarzynski, T., et al. (1996). Structure, 4(2), 1465–1474.
Nishida, S., et al. (2006). Journal of Biological Chemistry, 281, 1714–1724.
Anuradha, C.M., et al (2009). Available at Nature Precedings http://hdl.handle.net/10101/npre.2009.3731.1.
Eschenburg, S., et al. (2005). Journal of Biological Chemistry, 280, 14070–14075.
Kumar, V., et al. (2010). Journal of Molecular Modeling, 17(5), 939–953.
Weatherall, C., & Dible, J. H. (2005). Journal Bacteriology Pathology, 32(3), 413–417.
Online: http://ebookbrowse.com/poster-mura-medchemkongress-hd-032009-final-pdf-d99090931.
Acknowledgments
Authors acknowledge the financial support provided by the UGC-CSIR, New Delhi, India.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 3810 kb)
Rights and permissions
About this article
Cite this article
Kaur, N., Khokhar, M., Jain, V. et al. Identification of Druggable Targets for Acinetobacter baumannii Via Subtractive Genomics and Plausible Inhibitors for MurA and MurB. Appl Biochem Biotechnol 171, 417–436 (2013). https://doi.org/10.1007/s12010-013-0372-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-013-0372-2